The Relationship Between Cumulative Platinum-Based Chemotherapy Dose And The Occurrence Of Ototoxicity In Head And Neck Malignancies

Authors

  • Hendro Purnomo Department of Otorhinolaryngology, Faculty of Medicine, Diponegoro University Semarang, Indonesia
  • Dwi Marliyanti Department of Otorhinolaryngology, Faculty of Medicine, Diponegoro University Semarang, Indonesia
  • Muyassaroh Department of Otorhinolaryngology, Kariadi Hospital Semarang, Indonesia
  • Dian Ayu Ruspita Department of Otorhinolaryngology, Kariadi Hospital Semarang, Indonesia
  • Zulfikar Naftali Department of Otorhinolaryngology, Faculty of Medicine, Diponegoro University Semarang, Indonesia

DOI:

https://doi.org/10.36408/mhjcm.v11i2.1085

Keywords:

ototoxic, pure tone audiometry, chemotherapy, platinum

Abstract

BACKGROUND: Chemotherapy is a treatment for head and neck malignancies. Hearing impairment is a side effect of chemotherapy, especially caused by platinum-based chemotherapy. Hearing impairment generally occurs at high frequencies after the administration of chemotherapy.

AIMS: To prove assosciation between cumulative doses of platinum-based chemotherapy and ototoxic events in head and neck malignancies.

METHOD: This is a cross-sectional study. The sample is patients with head and neck malignancy receiving platinum-based chemotherapy at Dr. Kariadi Hospital Semarang from March to June 2023. Hearing assessment using pure tone audiometry was performed randomly at all chemotherapy cycles. Data was analyzed with a chi-square test.

RESULT:  Eighty-one subjects (52 male, 29 female), consisting of 71 subjects received cisplatin, and 10 subjects received carboplatin. Ototoxicity occurs in 91.7% of subjects receiving cumulative doses of cisplatin >300mg/m2 and carboplatin >1500mg/m2 compared to cumulative doses of cisplatin <300mg/m2 and carboplatin <1500mg/m2, which was 46.7% (p = 0.001, CI 1.416-2.725).

CONCLUSION: There was a significant association between cumulative doses of platinum-based chemotherapy and ototoxicity incidence of head and neck malignancy patients.

Downloads

Download data is not yet available.

References

1. Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32(3):178–86. DOI:10.1097/CCO.0000000000000629

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI:10.3322/caac.21492

3. To’bungan N, Aliyah SH, Wijayanti N, Fachiroh J. Epidemiologi, stadium, dan derajat diferensiasi kanker kepala dan leher. Biog J Ilm Biol. 2015;3:47–52. DOI:10.24252/bio.v3i1.566

4. Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2018;30(4):381–95. DOI:10.1016/j.coms.2018.06.001

5. Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37–50. DOI:10.1038/s41568-020-00308-y

6. Dilruba S, Kalayda G V. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2018;77(6):1103–24. DOI:10.1007/s00280-016-2976-z

7. Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70(3):177–84. DOI:10.1159/000093776

8. Monfared ZE, Khosravi A, Safavi Naini A, Radmand G, Khodadad K. Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: a Cohort, Prospective and Single Institute Study. Asian Pac J Cancer Prev. 2017;18(3):753–8. DOI:10.22034/APJCP.2017.18.3.753

9. Sriyapai T, Thongyai K, Phuakpet K, Vathana N, Buaboonnam J, Sanpakit K. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin. Turk J Pediatr. 2022;64(3):531–41. DOI:10.24953/turkjped.2021.5012

10. Edward ED, Rosdiana N, Farhat F, Siregar O, Lubis B. Prevalence and risk factors of hearing loss in children with solid tumors treated with platinum-based chemotherapy. Paediatr Indones. 2015;55(3 SE-Articles). DOI:10.14238/pi55.3.2015.121-5

11. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6(1):92. DOI:10.1038/s41572-020-00224-3

12. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6. DOI:10.1038/s41415-022-5166-x

13. Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int. 2021;2021:1738932. DOI:10.1155/2021/1738932

14. Razzaghdoust A, Mofid B, Peyghambarlou P. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. Support Care Cancer. 2020;28(1):155–61. DOI:10.1007/s00520-019-04780-7

15. Tang L-L, Chen Y-P, Chen C-B, Chen M-Y, Chen N-Y, Chen X-Z, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (London, England). 2021;41(11):1195–227. DOI:10.1002/cac2.12218

16. Tsvetkova D, Ivanova S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules. 2022;27(8). DOI:10.3390/molecules27082466

17. Aguiar PNJ, Tadokoro H, da Silva GF, Landgraf MM, Noia Barreto CM, Filardi BA, et al. Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. Future Oncol. 2016;12(23):2755–64. DOI:10.2217/fon-2016-0068

18. Patatt FSA, Gonçalves LF, Paiva KM de, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol. 2022;88(1):130–40. DOI: 10.1016/j.bjorl.2021.02.008

19. Apriliana C, Naftali Z, Yusmawan W. Decreased bone conduction value among nasopharing carcinoma with platinum based-cemotherapy: Combination of neoadjuvant paclitaxel-cisplatin and paclitaxel-carboplatin. J Kedokt Diponegoro. 2019;8(1). DOI:10.14710/dmj.v8i1.23300

20. Santosa YI, Samiadi D, Aroeman NA, Fianza PI. The effect of Tocoferol on Ototoxic effect of Cisplatin. Bandung Med J. 2012;44(4). DOI:10.15395/mkb.v44n4.176

21. Marcu LG. Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds. Pharmaceuticals (Basel). 2022;15(2). DOI:10.3390/ph15020255

22. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support care cancer Off J Multinatl Assoc  Support Care Cancer. 2006;14(3):223–9. DOI:10.1007/s00520-005-0868-6

23. Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, et al. Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. Oncologist. 2019;24(5):617–23. DOI:10.1634/theoncologist.2018-0298

24. Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Netw open. 2021;4(2):e2036695. DOI:10.1001/jamanetworkopen.2020.36695

Additional Files

Published

2024-07-31

How to Cite

1.
Purnomo H, Marliyawati D, Muyassaroh M, Ruspita DA, Naftali Z. The Relationship Between Cumulative Platinum-Based Chemotherapy Dose And The Occurrence Of Ototoxicity In Head And Neck Malignancies. Medica Hospitalia J. Clin. Med. [Internet]. 2024 Jul. 31 [cited 2024 Dec. 11];11(2):167-71. Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/1085

Issue

Section

Original Article

Citation Check